Published in Clin Exp Vaccine Res on January 30, 2015
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. Drug Saf (2015) 0.79
Innate Immune Memory: The Latest Frontier of Adjuvanticity. J Immunol Res (2015) 0.76
Establishment of specific cytotoxic T lymphocyte culture system and its inhibitory effect on ovarian cancer. Oncol Lett (2016) 0.75
Dendritic cell-based vaccines in treating recurrent herpes labialis: Results of pilot clinical study. Hum Vaccin Immunother (2016) 0.75
Self-assembly of polyphosphazene immunoadjuvant with poly(ethylene oxide) enables advanced nanoscale delivery modalities and regulated pH-dependent cellular membrane activity. Heliyon (2016) 0.75
The influence of adjuvant on UreB protection against Helicobacter pylori through the diversity of CD4+ T-cell epitope repertoire. Oncotarget (2017) 0.75
N-(2-hydroxy) propyl-3-trimethylammonium chitosan chloride: An immune-enhancing adjuvant for hepatitis E virus recombinant polypeptide vaccine in mice. Hum Vaccin Immunother (2017) 0.75
The putative role of environmental aluminium in the development of chronic neuropathology in adults and children. How strong is the evidence and what could be the mechanisms involved? Metab Brain Dis (2017) 0.75
Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet (2010) 26.48
Toll-like receptors and innate immunity. Nat Rev Immunol (2001) 16.50
A role for mitochondria in NLRP3 inflammasome activation. Nature (2010) 13.21
The ClinicalTrials.gov results database--update and key issues. N Engl J Med (2011) 9.83
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature (2008) 9.16
Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol (2010) 8.87
Innate immunity: impact on the adaptive immune response. Curr Opin Immunol (1997) 5.62
Vaccine adjuvants: putting innate immunity to work. Immunity (2010) 5.02
Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol (2011) 3.25
Aluminium compounds for use in vaccines. Immunol Cell Biol (2004) 2.99
Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med (2011) 2.82
Vaccine adjuvants: current state and future trends. Immunol Cell Biol (2004) 2.74
Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann Intern Med (2014) 2.67
Key roles of adjuvants in modern vaccines. Nat Med (2013) 2.62
Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol (2009) 2.47
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A (2009) 2.42
The effect of paraffin oil and mycobacteria on antibody formation and sensitization; a review. Am J Clin Pathol (1951) 2.36
Reverse vaccinology. Curr Opin Microbiol (2000) 2.36
Vaccines for the twenty-first century society. Nat Rev Immunol (2011) 2.34
B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev (2000) 2.17
Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ (2008) 2.16
The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol (2014) 1.98
Biomaterials based on chitin and chitosan in wound dressing applications. Biotechnol Adv (2011) 1.78
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine (2011) 1.77
Accelerating next-generation vaccine development for global disease prevention. Science (2013) 1.73
Vaccines: past, present and future. Nat Med (2005) 1.73
Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) (2005) 1.65
Contagious diseases in the United States from 1888 to the present. N Engl J Med (2013) 1.54
Towards the endgame and beyond: complexities and challenges for the elimination of infectious diseases. Philos Trans R Soc Lond B Biol Sci (2013) 1.51
Immunity induced by a broad class of inorganic crystalline materials is directly controlled by their chemistry. J Exp Med (2014) 1.49
The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol (2010) 1.45
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A (2011) 1.44
Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine (2002) 1.41
The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf (2002) 1.39
The history of MF59(®) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines (2013) 1.39
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine (2006) 1.38
Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine (2004) 1.36
Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.32
Antigen depot is not required for alum adjuvanticity. FASEB J (2011) 1.28
Chitin, chitinases and chitinase-like proteins in allergic inflammation and tissue remodeling. Yonsei Med J (2009) 1.26
Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev (2009) 1.26
Safety of human papillomavirus vaccines: a review. Drug Saf (2013) 1.25
Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol (2009) 1.24
Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar Drugs (2010) 1.22
Immunological activity of chitin and its derivatives. Vaccine (1984) 1.19
Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci U S A (2009) 1.18
The future of human DNA vaccines. J Biotechnol (2012) 1.18
Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol (1995) 1.17
Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine (2012) 1.13
Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol (2013) 1.13
TLR8: the forgotten relative revindicated. Cell Mol Immunol (2012) 1.12
Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation. J Leukoc Biol (2013) 1.10
The rate of interleukin-1beta secretion in different myeloid cells varies with the extent of redox response to Toll-like receptor triggering. J Biol Chem (2011) 1.09
The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res (1946) 1.09
Precipitated Toxoid as an Immunizing Agent Against Diphtheria. Am J Public Health Nations Health (1934) 1.08
Meningococcal disease and travel. Clin Infect Dis (2001) 1.08
Vaccines, new opportunities for a new society. Proc Natl Acad Sci U S A (2014) 1.06
Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience. Vaccine (2012) 1.06
The role of NOD-like Receptors in shaping adaptive immunity. Curr Opin Immunol (2010) 1.04
Risk of occupationally acquired illnesses from biological threat agents in unvaccinated laboratory workers. Biosecur Bioterror (2004) 1.02
Diphtheria Toxin-Antitoxin and Toxoid : A Comparison. Am J Public Health Nations Health (1932) 1.02
Eradication of vaccine-preventable diseases. Annu Rev Public Health (1999) 1.00
From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol (2014) 1.00
Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med (2011) 1.00
Use of back-scatter electron signals to visualise cell/nanowires interactions in vitro and in vivo; frustrated phagocytosis of long fibres in macrophages and compartmentalisation in mesothelial cells in vivo. Part Fibre Toxicol (2012) 0.99
Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles. ACS Nano (2013) 0.99
Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development. J Biomed Biotechnol (2012) 0.98
Role of adjuvants in modeling the immune response. Curr Opin HIV AIDS (2010) 0.96
Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine (2011) 0.96
The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur J Immunol (2012) 0.95
A reduction in chronic hepatitis B virus infection prevalence among children in Vietnam demonstrates the importance of vaccination. Vaccine (2013) 0.95
The eradication of smallpox--an overview of the past, present, and future. Vaccine (2011) 0.94
Chitosan solution enhances the immunoadjuvant properties of GM-CSF. Vaccine (2007) 0.94
Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. Int Rev Immunol (2013) 0.94
Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants. Immunol Cell Biol (2014) 0.94
Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccin (2011) 0.93
Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect Immun (2001) 0.93
Adjuvant influenza vaccines. Bull World Health Organ (1969) 0.93
Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity. Future Microbiol (2010) 0.92
Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine (2006) 0.91
Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant. Vaccine (2013) 0.91
Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine (2008) 0.90
Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules (2005) 0.90
Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine (1998) 0.89
The effect of stable macromolecular complexes of ionic polyphosphazene on HIV Gag antigen and on activation of human dendritic cells and presentation to T-cells. Biomaterials (2014) 0.89
In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations. Vaccine (2013) 0.89
A review of the burden of disease due to otitis media in the Asia-Pacific. Int J Pediatr Otorhinolaryngol (2012) 0.88
Safety profile of the yellow fever vaccine Stamaril®: a 17-year review. Expert Rev Vaccines (2013) 0.88
Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles. J Control Release (2013) 0.88
AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine (2010) 0.87
Adjuvanticity effect of sodium alginate on subcutaneously injected BCG in BALB/c mice. Microbes Infect (2008) 0.87
Strategies to eliminate HBV infection. Future Virol (2014) 0.87
Unequivocal identification of intracellular aluminium adjuvant in a monocytic THP-1 cell line. Sci Rep (2014) 0.87
Vaccine adjuvant formulations: a pharmaceutical perspective. Semin Immunol (2013) 0.86
Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant. J Immunol (2014) 0.86
Structure and adsorption properties of commercial calcium phosphate adjuvant. Vaccine (2004) 0.86
Notes on the Production of Immunity to Diphtheria Toxin. J Hyg (Lond) (1921) 0.86
Combination of adjuvants: the future of vaccine design. Expert Rev Vaccines (2013) 0.86
Toll-like receptors in wound healing: location, accessibility, and timing. J Invest Dermatol (2012) 0.85
Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation. Expert Rev Vaccines (2014) 0.85